aflibercept vs brimonidine/timolol
Side-by-side comparison of aflibercept and brimonidine/timolol Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Eylea
Combigan
AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
Combigan eye drops contain two medicines that lower pressure in the eye. It is used to treat glaucoma or high pressure in the eye.
AHZANTIVE treats wet age-related macular degeneration (AMD). It also treats swelling in the macula (the central part of the retina) caused by retinal vein occlusion (RVO) or diabetic macular edema (DME). Additionally, it can treat diabetic retinopathy (DR), an eye disease caused by diabetes.
Combigan is used to lower high pressure in your eyes. This medicine is for people with glaucoma or ocular hypertension. It is for those who need more help than one medicine can provide. Combigan helps lower the pressure in your eye.
AHZANTIVE is a VEGF inhibitor. VEGF is a protein that promotes the growth of new blood vessels. By blocking VEGF, AHZANTIVE helps to reduce the growth of abnormal blood vessels in the eye and decrease leakage.
Combigan has two drugs that work together to lower eye pressure. Brimonidine lowers fluid production in the eye and increases fluid drainage. Timolol reduces fluid production.
- • Bleeding in the eye
- • Eye pain
- • Clouding of the lens of the eye (cataract)
- • Separation of the vitreous gel from the retina
- • Spots in your vision
- • Allergic conjunctivitis (eye allergy)
- • Conjunctival folliculosis (bumps on the eye)
- • Conjunctival hyperemia (redness of the eye)
- • Eye itching
- • Eye burning
- Death 7,853
- Trouble seeing 2,013
- Using the medicine for something it's not approved for 1,509
- Loss of sight 1,459
- Eye infection 1,372
- The medicine is not working 2,756
- The medicine is not effective 553
- Allergic reaction 440
- Using the medicine for something it's not approved for 261
- Tiredness 240
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina. Tell your doctor right away if you have any signs of these problems. AHZANTIVE may also increase the risk of blood clots that can cause stroke or heart attack.
Combigan contains timolol, which can cause serious heart and breathing problems. These problems can be more likely if you have asthma, COPD, or heart failure. Tell your doctor if you have any of these conditions.
It is not known if AHZANTIVE can harm an unborn baby. AHZANTIVE should be used during pregnancy only if the benefit justifies the risk. It is also not known if AHZANTIVE passes into breast milk.
Animal studies suggest possible risk to the fetus. Tell your doctor if you are pregnant or plan to become pregnant. Timolol can pass into breast milk, so talk to your doctor about breastfeeding while using Combigan.
Also Compare — Nearby Drugs
Compare aflibercept with
How to Read This aflibercept vs brimonidine/timolol Comparison
aflibercept is classified in the Anti-VEGF (Ophthalmic Injection) drug class, while brimonidine/timolol sits within the Alpha-2 Agonist / Beta-Blocker Combination class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aflibercept has 14,206 submissions while brimonidine/timolol has 4,250. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aflibercept and brimonidine/timolol — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.